Compositions and methods for the targeting of SOD1
Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.
1. A composition comprising a CasX variant protein comprising the sequence of SEQ ID NO: 126, or a sequence having at least 90% sequence identity thereto, and a first guide ribonucleic acid (gRNA), wherein the CasX variant protein is a chimeric CasX protein comprising protein domains from two or more different CasX proteins, and wherein the gRNA comprises a targeting sequence complementary to a superoxide dismutase 1 (SOD1) gene target nucleic acid sequence comprising one or more mutations.
2. The composition of claim 1 , wherein the one or more mutations are in a region selected from the group consisting of:
a) a SOD1 intron;
b) a SOD1 exon;
c) a SOD1 intron-exon junction;
d) a SOD1 regulatory element; and
e) an intergenic region.
3. The composition of claim 1 , wherein the one or more mutations comprise an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides as compared to a wild-type SOD1 gene sequence.
4. The composition of claim 3 , wherein the one or more mutations comprise a gain of function mutation.
5. The composition of claim 1 , wherein the one or more mutations in the SOD1 gene target nucleic acid sequence encode a mutation selected from the group consisting of A4S, A4T, A4V, C6F, V7E, L8Q, L8V, G12R, V14G, V14M, G16S, F20C, E21G, E21K, Q22L, G37R, L38R, L38V, G41D, G41S, H43R, F45C, H46R, H48Q, H48R, E49K, T54R, N65S, L67P, L67R, G72S, D76Y, H80A, L84F, L84V, G85R, N86S, V87A, A89T, A89V, D90A, D90V, G93A, G93C, G93D, G93R, G93V, A95G, V97M, E100G, E100K, D101G, D101N, I104F, S105L, L106V, G108V, C111Y, I112M, I112T, I113T, G114A, R115G, V118L, D124G, D124V, D125H, L126S, S134N, N139K, L144F, L144S, A145T, C146R, G147R, V148G, V148 I, 1149T, and I151T relative to the wild-type superoxide dismutase 1 protein sequence of SEQ ID NO: 100 without the N-terminal methionine.
6. The composition of claim 1 , wherein the SOD1 gene encodes a protein comprising an A4V substitution, a D90A substitution or a G93A substitution compared to the wild-type superoxide dismutase 1 protein sequence of SEQ ID NO: 100 without the N-terminal methionine.
7. The composition of claim 1 , wherein the SOD1 gene encodes a non-functional superoxide dismutase 1 protein.
8. The composition of claim 1 , wherein the gRNA is a single-molecule gRNA (sgRNA).
9. The composition of claim 1 , wherein the targeting sequence of the gRNA comprises a ribonucleic acid (RNA) sequence selected from the group consisting of the sequences of SEQ ID NOS: 351-357, 370, and 371, or a sequence having at least 90% identity thereto.
10. The composition of claim 1 , wherein the targeting sequence of the gRNA is complementary to a sequence of a SOD1 exon, to a sequence of a SOD1 intron, to a sequence of a SOD1 intron-exon junction, to a sequence of a SOD1 regulatory element, to a sequence of a sequence of an intergenic region of the SOD1 gene or to a sequence comprising one or more single nucleotide polymorphisms (SNPs) of the SOD1 gene.
11. The composition of claim 1 , wherein the targeting sequence of the gRNA is complementary to a sequence of a SOD1 exon 1 or complementary to a target nucleic acid sequence encoding a A4V substitution, a D90A substitution or a G93A substitution compared to the wild-type superoxide dismutase 1 protein sequence of SEQ ID NO: 100 without the N-terminal methionine.
12. The composition of claim 1 , further comprising a second gRNA, wherein the second gRNA has a targeting sequence complementary to a different or overlapping portion of the SOD1 target nucleic acid compared to the targeting sequence of the first gRNA.
13. The composition of claim 12 , wherein the first or second gRNA has a scaffold comprising the sequence of SEQ ID NO: 2238, or a sequence having at least 70% identity thereto.
14. The composition of claim 1 , wherein the CasX variant protein further comprises one or more nuclear localization signals (NLS).
15. The composition of claim 1 , further comprising a donor template nucleic acid.
16. The composition of claim 1 , wherein the chimeric CasX protein comprising protein domains from two or more different CasX proteins, comprises proteins domains from two or more different reference CasX proteins.
17. The composition of claim 1 , wherein the chimeric CasX protein comprising protein domains from two or more different CasX proteins, comprises proteins domains from two or more different CasX variant proteins.
18. A composition comprising a CasX variant protein comprising the sequence of SEQ ID NO: 126, or a sequence having at least 90% sequence identity thereto, and a first guide ribonucleic acid (gRNA), wherein the gRNA has a scaffold comprising a sequence having at least 70% sequence identity to the sequence of SEQ ID NO: 2238, and wherein the gRNA comprises a targeting sequence complementary to a superoxide dismutase 1 (SOD1) gene target nucleic acid sequence comprising one or more mutations.
19. The composition of claim 18 , wherein the SOD1 gene comprises one or more mutations in a region selected from the group consisting of:
a) a SOD1 intron;
b) a SOD1 exon;
c) a SOD1 intron-exon junction;
d) a SOD1 regulatory element; and
e) an intergenic region.
20. The composition of claim 18 , wherein the SOD1 gene comprising a mutation encodes a protein comprising a A4V substitution, a D90A substitution, or a G93A substitution compared to the wild-type superoxide dismutase 1 protein sequence of SEQ ID NO: 100 without the N-terminal methionine.
21. The composition of claim 18 , wherein the targeting sequence of the gRNA comprises a sequence selected from the group consisting of the sequences of SEQ ID NOS: 351-357, 370, and 371, or a sequence having at least 90% identity thereto.
22. A nucleic acid vector:
(a) encoding a CasX variant protein, the CasX variant protein comprising the sequence of SEQ ID NO: 126, or a sequence having at least 90% sequence identity thereto; and
(b) encoding a guide ribonucleic acid (gRNA), wherein the gRNA has a scaffold comprising a sequence having at least 70% sequence identity to the sequence of SEQ ID NO: 2238, and wherein the gRNA comprises a targeting sequence complementary to a superoxide dismutase 1 (SOD1) gene target nucleic acid sequence comprising one or more mutations.
23. The nucleic acid vector of claim 22 , wherein the targeting sequence of the gRNA comprises a ribonucleic acid sequence selected from the group consisting of the sequences of SEQ ID NOS: 351-357, 370, and 371, or a sequence having at least 90% identity thereto.
24. The nucleic acid vector of claim 22 , wherein the nucleic acid vector is as an adeno-associated viral (AAV) vector.
25. A composition comprising:
(a) a CasX variant protein, or a sequence encoding the CasX variant protein, the CasX variant protein comprising the sequence of SEQ ID NO: 126, or a sequence having at least 90% sequence identity thereto; and
(b) a guide ribonucleic acid (gRNA), wherein the gRNA has a scaffold comprising a sequence having at least 70% sequence identity to the sequence of SEQ ID NO: 2238, and wherein the gRNA comprises a targeting sequence complementary to a superoxide dismutase 1 (SOD1) gene target nucleic acid sequence comprising one or more mutations.